Labcorp completes acquisition of BioReference Health oncology assets

Labcorp (LH) has completed the acquisition of BioReference Health's U.S. oncology and oncology-related clinical testing assets for up to $225 million, strengthening its diagnostic capabilities and market presence in a critical growth sector. This strategic expansion follows recent positive developments for Labcorp, including the launch of the first FDA-cleared blood test for Alzheimer's disease and robust Q2 2025 financial results that exceeded analyst expectations, leading to increased price targets from several firms. OPKO Health (OPK), the seller, intends to utilize a portion of the proceeds to fund its expanded share repurchase authorization.

Analysis

Labcorp (LH) is demonstrating strong execution on a multi-pronged growth strategy, combining strategic M&A, product innovation, and robust organic performance. The acquisition of BioReference Health's U.S. oncology testing assets for up to $225 million immediately strengthens Labcorp's footprint in a critical, high-growth diagnostic sector. This move is supported by a strong balance sheet, evidenced by its $13.5 billion in annual revenue and capacity for such transactions. This inorganic growth is complemented by significant internal developments, most notably the launch of the first FDA-cleared blood test for Alzheimer's disease, a breakthrough with substantial market potential. Furthermore, the company's Q2 2025 financial results surpassed analyst expectations, with adjusted EPS of $4.35 on $3.53 billion in revenue, beating forecasts of $4.17 and $3.48 billion, respectively. This strong performance has prompted positive analyst revisions, with firms like Jefferies, Evercore ISI, and Leerink Partners raising price targets to the $300-$323 range. For OPKO Health (OPK), the divestiture represents a strategic refocusing on its core clinical operations and 4Kscore Test franchise, with the proceeds intended to fund an expanded share repurchase authorization.

Key Decisions for Investors

• Given Labcorp's strategic acquisition in oncology, a landmark FDA-cleared Alzheimer's test, and a strong earnings beat, investors should consider the recent developments as reinforcing a bullish thesis, supported by multiple analyst price target upgrades.
• Investors should monitor the integration of the acquired BioReference assets and the commercial adoption of the new Alzheimer's test, as successful execution in these areas is crucial to realizing the company's projected growth.
• For those holding OPKO Health, the asset sale provides immediate capital for shareholder-friendly buybacks but also necessitates a re-evaluation of the company's long-term growth trajectory following the divestiture of its U.S. oncology business.